PhoreMost® is focused on bringing more effective and affordable targeted medicines to patients


Full video

CRYPTIC DRUG SITES

 

SITESEEKER®

Phenotypic mining for druggable targets 

PHENOTYPIC DISEASE LINKAGE

 

PhoreMost® has developed a next-generation phenotypic screening platform called 'SITESEEKER' to identify the best new targets for future therapy, and crucially, how to drug them. This has the potential to significantly increase the diversity of novel therapeutics for cancer and other unmet diseases, where treatment options are currently severely limited.

seeker.png

SITESEEKER

Based on the Company’s proprietary PROTEINi® (Protein Interference) technology, PhoreMost has developed SITESEEKER; a platform that can systematically unmask hidden, or ”cryptic” druggable sites in the human genome and directly link them to useful therapeutic functions in a live-cell context. Using SITESEEKER, PhoreMost is building a pipeline of validated targets and drug discovery programs for further development, both internally and in partnership.

find out more

Leadership Team


Chris Torrance

Founder / Chief Executive Officer

Dr Chris Torrance is a cancer researcher and entrepreneur. In 2007 he founded Horizon Discovery to translate advances in human genome editing into a range of research tools and services to accelerate the discovery of new and improved ‘Personalized Medicines’, including the identification of novel drug targets for pharmaceutical development.

Ashok Venkitaraman

Founder / Company Director

Ashok is the Ursula Zoellner Professor of Cancer Research at the University of Cambridge, and the Director of the Medical Research Council (MRC) Cancer Unit there. He is a physician-scientist who qualified in medicine at the Christian Medical College, Vellore, India, before completing his Ph.D. at University College London, and his postdoctoral work at the MRC Laboratory of Molecular Biology in Cambridge. Ashok’s first faculty position was also at the MRC Laboratory of Molecular Biology, before his election as the inaugural holder of the Zoellner Professorship. 

Hermann Hauser

Company Director

Serial Entrepreneur and Co-founder of Amadeus Capital Partners, Dr Hermann Hauser CBE has wide experience in developing and financing companies in the information technology sector. He co-founded a number of high-tech companies including Acorn Computers which spun out ARM, E-trade UK, Virata and Cambridge Network. Subsequently Hermann became vice president of research at Olivetti. During his tenure at Olivetti, he established a global network of research laboratories. Since leaving Olivetti, Hermann has founded over 20 technology companies. 

Neil Torbett

Chief Business Officer

Neil is an experienced biotechnology professional with expertise in commercialising technology in the areas of biomarker, target and drug discovery.

Markus Muellner

Chief Technology Officer

Markus joined PhoreMost in 2015 from Vienna Austria as the Head of R&D and set up PhoreMosts’ SITESEEKER® screening platform.

Grahame McKenzie

Founder / Chief Scientific Officer

Grahame is a biologist with 15 years of experience in academic and industrial drug discovery.

Jonathan Milner

Chairman / Company Director

Jonathan, Founder and currently Deputy Chairman of Abcam plc, is an experienced entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups.

Rich Boyce

Director of Chemistry

Rich is a medicinal chemist with over 20 years’ experience in drug discovery in oncology, inflammation and metabolic disease areas.

Upcoming Events

April 14-18 2018, AACR Annual Meeting 2018, Chicago
April 17-18 2018, ELRIG - Research & Innovation 2018, Cambridge

Twitter



Contact

T +44 (0)1223 804 161

info@phoremost.com